Daewoong Pharmaceutical Antiplatelet Agent, Research Published in SCI-Level Academic Journal

Anplewon Seobangjeong 300mg
Early Restenosis Prevention Effect and Safety After Vascular Intervention

Daewoong Pharmaceutical announced on the 28th that a study on the efficacy and safety of 'Anplone Extended-Release Tablets 300mg (active ingredient: Sarpogrelate Hydrochloride)' was recently published in the SCI-level international journal 'Scientific Reports.' Scientific Reports is an online open-access journal of the world-renowned international journal Nature.

Anplone is an antiplatelet agent containing sarpogrelate, launched by Daewoong Pharmaceutical in 2015. Sarpogrelate is a selective serotonin (5-HT2A) receptor antagonist that acts on platelets and blood vessels to inhibit vascular occlusion. Through this mechanism, it improves ischemic symptoms such as ulcers, pain, and cold sensation caused by chronic arterial occlusive disease. Anplone is available in two dosages: extended-release 300mg and regular 100mg tablets, allowing easy dose adjustment according to patient characteristics.

The published study analyzed the early restenosis prevention effect and safety of Anplone Extended-Release Tablets 300mg after dual antiplatelet therapy (DAPT) in 272 subjects who underwent femoropopliteal artery endovascular intervention at 10 medical institutions, including Seoul National University Hospital.

The clinical trial randomly assigned subjects to the ▲'Anplone Extended-Release' group (Anplone Extended-Release 300mg and aspirin 100mg, 133 patients) and ▲'Clopidogrel' group (Clopidogrel 75mg and aspirin 100mg, 137 patients), administering the drugs orally once daily for 6 months, then compared the restenosis rate of the target artery and safety indicators.

Results showed that at 6 months, the restenosis rate of the target vessel tended to be lower in the Anplone Extended-Release group (13%) compared to the Clopidogrel group (19%). This established the non-inferiority of sarpogrelate compared to clopidogrel. Safety indicator comparisons revealed no significant differences between the two groups, indicating similar safety profiles.

Professor Min Seung-gi, vascular transplant surgery specialist at Seoul National University Hospital and lead researcher of the study, stated, "The SAFE study is the first to demonstrate the efficacy of Anplone Extended-Release 300mg in dual antiplatelet therapy for early restenosis prevention after femoropopliteal artery endovascular intervention. By proving non-inferiority in efficacy and safety, it can establish itself as a new option to replace clopidogrel in patients with peripheral arterial disease after vascular intervention."

Park Eun-kyung, head of ETC Marketing at Daewoong Pharmaceutical, said, "Based on continuous research, Anplone will establish itself as 'one of them' in the dual antiplatelet therapy prescription market and contribute to the prevention and treatment of peripheral arterial disease in Koreans entering a super-aged society."

Daewoong Pharmaceutical Anplewon Sustained Release Tablet 300mg. [Image provided by Daewoong Pharmaceutical]